Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs

Davies, Geraint ORCID: 0000-0002-3819-490X, Boeree, Martin, Hermann, Dave and Hoelscher, Michael (2019) Accelerating the transition of new tuberculosis drug combinations from Phase II to Phase III trials: New technologies and innovative designs. PLOS MEDICINE, 16 (7). e1002851-.

Access the full-text of this item by clicking on the Open Access link.

Official URL: http://dx.doi.org/10.1371/journal.pmed.1002851

Abstract

Geraint Davies and colleagues discuss the potential for innovative early-phase clinical trial methods and technologies to reduce risk and speed up drug development for tuberculosis.

Item Type:	Article
Uncontrolled Keywords:	Humans, Tuberculosis, Antitubercular Agents, Treatment Outcome, Drug Therapy, Combination, Risk Assessment, Risk Factors, Research Design, Clinical Trials, Phase II as Topic, Clinical Trials, Phase III as Topic, Workflow, Patient Safety, Drug Development
Depositing User:	Symplectic Admin
Date Deposited:	12 Aug 2019 13:56
Last Modified:	19 Jan 2023 00:31
DOI:	10.1371/journal.pmed.1002851
Open Access URL:	https://journals.plos.org/plosmedicine/article/fil...
Related URLs:	Author Publisher
URI:	https://livrepository.liverpool.ac.uk/id/eprint/3051540